Gilead Sciences
Apr 17, 2012 at 08:32 | Source: Reuters
Oct 28, 2011 at 19:37 | Source: PTI
Jul 12, 2011 at 22:41 | Source: PTI
Jul 12, 2011 at 21:45 | Source: CNBC-TV18
Jul 12, 2011 at 15:28 | Source: PTI
Mar 16, 2011 at 16:29 | Source: CNBC-TV18
News across the web »
May 12, 2012 at 02:00 | Source: Business Week
May 09, 2012 at 02:02 | Source: Wall Street Journal
Apr 28, 2012 at 08:32 | Source: Economic Times
Apr 27, 2012 at 01:12 | Source: Market Watch
Apr 21, 2012 at 22:00 | Source: Bloomberg
Interact & exchange stock tips & market info »
Related News »
Perception, Opportunity in Volatility - Research & Analysis on Gilead Sciences, Inc. and International Business Machines Corp. HONG KONG -- (Marketwire) -- 05/29/12 -- This morning, www.MarketFoundations.com announced new reports highlighting ...
May 29, 2012 at 13:21 | Source: Bloomberg
Gilead Sciences Inc. (GILD) is an innovative healthcare company with a strong record of historical earnings growth and expectations for above-average growth into the future. Nevertheless, Mr. Market seems unwilling to recognize the past and ...
May 21, 2012 at 17:41 | Source: GuruFocus
Recently, Gilead Sciences, Inc. ( GILD) announced that its marketing application seeking approval for its candidate cobicistat in the EU has been validated by the European Medicines Agency (EMA). The marketing authorization application (MAA) was filed by ...
May 24, 2012 at 20:37 | Source: NASDAQ
Gilead Sciences, Inc. (Nasdaq:GILD - News) announced today that the Marketing Authorisation Application (MAA) for cobicistat, submitted on April 26, 2012, has been validated by the European Medicines Agency (EMA). Cobicistat is Gilead’s ...
May 23, 2012 at 20:02 | Source: Yahoo Finance
(RTTNews.com) - Gilead Sciences Inc. (GILD) announced that the Marketing Authorisation Application or MAA for cobicistat, submitted on April 26, 2012, has been validated by the European Medicines Agency or EMA. Cobicistat is Gilead's ...
May 22, 2012 at 23:52 | Source: NASDAQ
The outlook for Gilead Sciences (NASDAQ:GILD) brightened substantially last week. A U.S. government advisory panel recommended approval of Quad, the company’s experimental four-in-one HIV drug, and the off-label use of Truvada, an existing ...
May 17, 2012 at 13:57 | Source: Investorplace.com
Gilead Sciences (NASDAQ: GILD)‘s stock had its “overweight” rating reiterated by investment analysts at JPMorgan Chase (NYSE: JPM) in a note issued to investors on Wednesday. They currently have a $65.00 target price on the stock. The analysts wrote ...
May 16, 2012 at 19:56 | Source: zolmax.com
Gilead Sciences, Inc. - Product Pipeline Review - 2012 - Our pharmaceuticals report, Gilead Sciences, Inc. - Product Pipeline Review - 2012 provides data on the Gilead Sciences, Inc.'s research and development focus. The report includes information on ...
May 17, 2012 at 12:31 | Source: Transworld News
Analysts have spotted a possible bearish inside day candle pattern in Gilead Sciences (NASDAQ:GILD) based on the price action in the company's shares. Yesterday's price range of $51.67 and $52.36 is within the prior day's high and low of the day.
May 16, 2012 at 12:04 | Source: Financial News Network Online
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single ...
May 10, 2012 at 23:59 | Source: Business Wire